Skip to main content
. 2013 May 3;8(5):e62679. doi: 10.1371/journal.pone.0062679

Figure 4. Physostigmine and neostigmine reduce surgery combined with LPS-induced IL-1beta and TNF-alpha protein expression in spleen and plasma.

Figure 4

IL-1-alpha, TNF-alpha and IL-10 were measured by Cytometric bead array analysis in spleen (A–C) and plasma (D–F) samples 1 h postintervention. Surgery and LPS-treatment resulted in an increased protein expression of IL-1alpha and TNF-alpha in the spleen after 1 h. Treatment with the AChE inhibitors physostigmine and neostigmine significantly reduced the expression of IL-1alpha in the spleen. In plasma, surgery accompanied by LPS-treatment caused an increased protein expression of TNF-alpha and IL-10. TNF-alpha concentration was significantly diminished by physostigmine and neostigmine application, whereas the expression of IL-10 did not change significantly. Additionally, IL-1beta expression was quantified by western blot analysis in spleen samples extracted 1 h postintervention (G–H). Surgery and LPS-treatment resulted in an increased protein expression of IL-1beta in the spleen after 1 h. Treatment with the AChE inhibitors physostigmine and neostigmine significantly reduced the expression of IL-1beta in the spleen. Results of Cytometric bead array and western blot analysis are shown as mean ± SEM (n = 8 per group). ***P<0.001, **P<0.01 represent the difference between LPS and saline treated groups. #P<0.05, ##P<0.01 represent the difference between LPS and physostigmine or neostigmine treated groups.